The Assessment of Smart Phone Everyday Tasks (ASSET): A new IADL test for early AD
L
Liana Apostolova, MD
Primary Investigator
Enrolling By Invitation
55 years - 90 years
All
Phase
N/A
12 participants needed
3 Locations
Brief description of study
What is the purpose of this study?
The overall goal of this project is to validate a novel performance-based IADL instrument that uses a smartphone to assess healthcare-related daily activities, ASSET. This IADL test has been designed to tap the high-level tasks that challenge seniors in daily life, to serve as a clinically meaningful outcome measure for preclinical and prodromal AD trials, and to be easy and quick to administer, using real-life devices.
This study is being funded by the National Institutes of Health (NIH).
THIS STUDY IS ENROLLING BY INVITATION ONLY
Detailed description of study
What will happen during the study?
- This study will involve 1 prescreening visit over the telephone lasting approximately 10 minutes, 2 clinic visits at MGH added to an annual visit at the Massachusetts Alzheimer’s Disease Research Center (MADRC) (adding about 25 minutes per visit), and 11 remote/at-home visits lasting about 15 minutes. Thus, study participation will last about 12 months or 1 year.
- Participants will undergo ASSET, subjective IADL tests, and a neuropsychological test battery in the clinic at baseline and 1 year later.
- Participants will also undergo ASSET remotely/at-home on a monthly basis using alternate versions over the 12 months.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Healthy, Alzheimer's Disease, Dementia, ADRD, MIld cognitive impairment, MCI, subjective cognitive decline, SCD
-
Age: 55 years - 90 years
-
Gender: All
General inclusion criteria:
- Must be in general good health or have stable medical problems
- Fluent in English
- Have a study partner able to provide collateral information about the participant’s cognition, daily functioning, and behavior.
CN participants:
- Ages 65-90</li>
- Will be diagnosed as CN at the ADRC performance site initially by a single investigator and then followed by the final consensus diagnosis process as described above. Additionally, participants will have a CDR global score of 0.
SCD participants:
- Ages 65-90</li>
- Same criteria as CN participants or a diagnosis of “Impaired, not MCI” with a CDR global score of 0 or 0.5.
- Additionally, participants will have significant subjective memory concerns that indicate a higher likelihood of preclinical AD according to the conceptual framework outlined by the SCD Initiative working group14. Specifically, participants will be included in the SCD group if they endorse a persistent, recent change in their memory with an associated concern, based on the following 2 questions: 1) Have you experienced a change in your memory in the last 1-3 years? and 2) Are you concerned about this change? Responses will be on a Likert scale: “Not at all,” “Slightly,” “Moderately,” “Considerably,” and “Extremely.” If participants endorse “Slightly” or worse to both questions, they will be categorized as SCD.
MCI participants:
- Ages 55-90</li>
- Will be diagnosed as amnestic MCI (single or multiple domain) at the ADRC performance site initially by a single investigator and then followed by the final consensus diagnosis process as described above. Additionally, participants will have a CDR global score of 0.5 (with memory box score of 0.5 or 1).
Exclusion criteria:
- Significant cerebrovascular disease or psychiatric disorders
Updated on
19 Dec 2024.
Study ID: NEUR-MGB-ASSET, 20013
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
